[{"id":"67917d6a-e1b0-409b-853a-7e9fd258dd6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06802523","created_at":"2025-02-25T16:34:56.075Z","updated_at":"2025-02-25T16:34:56.075Z","phase":"Phase 1","brief_title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT06802523","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine) • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-07"},{"id":"8b14bf99-2f4f-4d08-a7e0-83d152f96cb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03867682","created_at":"2021-01-18T19:04:27.493Z","updated_at":"2024-07-02T16:35:41.038Z","phase":"Phase 1/2","brief_title":"Venetoclax and Lintuzumab-Ac225 in AML Patients","source_id_and_acronym":"NCT03867682","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Erbitux (cetuximab) • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-08-04"},{"id":"38d70ca6-e60e-428e-839b-b4649d1ec035","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932318","created_at":"2021-01-18T19:22:10.225Z","updated_at":"2024-07-02T16:35:42.415Z","phase":"Phase 1/2","brief_title":"Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients","source_id_and_acronym":"NCT03932318","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Erbitux (cetuximab) • azacitidine • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-07-20"},{"id":"a7cfcc21-cc8b-4a64-9046-59fd8a1f40d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02575963","created_at":"2021-01-18T12:29:18.783Z","updated_at":"2024-07-02T16:35:42.400Z","phase":"Phase 1/2","brief_title":"Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients","source_id_and_acronym":"NCT02575963","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cytarabine • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2023-07-20"},{"id":"1f2d0edd-3aa3-4ee5-bf61-cd430b705bcf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03705858","created_at":"2021-01-18T18:09:32.951Z","updated_at":"2024-07-02T16:37:02.100Z","phase":"Phase 1","brief_title":"Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03705858","lead_sponsor":"Joseph Jurcic","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actimab-A (lintuzumab-Ac225) • Zamyl (lintuzumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 02/28/2019","primary_completion_date":" 02/28/2019","study_txt":" Completion: 02/28/2019","study_completion_date":" 02/28/2019","last_update_posted":"2019-03-08"},{"id":"da35062e-384e-4dbb-94cd-bedee3db4566","acronym":"","url":"https://clinicaltrials.gov/study/NCT01756677","created_at":"2021-01-18T07:42:59.855Z","updated_at":"2024-07-02T16:37:17.320Z","phase":"Phase 1/2","brief_title":"Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients","source_id_and_acronym":"NCT01756677","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cytarabine • Actimab-A (lintuzumab-Ac225) • Depocyte (liposomal cytarabine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-04"}]